What is NewGenIvf Group's operating income?

NewGenIvf Group's total operating income in 2025 was -$10.73 million, based on the following breakdown: Total Gross Profit: $955.85 thousand Total Operating Expenses: $11.68 million

NewGenIvf Group (NIVF) Financials

$0.50 -0.20 (-28.52%)

As of 10:30 AM Eastern

Compare

Annual Income Statements for NewGenIvf Group

This table shows NewGenIvf Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-0.00	0.46	0.13	-0.52	9.88
Consolidated Net Income / (Loss)	-0.14	0.59	0.24	-1.00	20
Net Income / (Loss) Continuing Operations	-0.14	0.14	0.11	-0.47	9.73
Total Pre-Tax Income	0.16	0.34	0.11	-0.96	9.73
Total Operating Income	0.20	0.40	0.04	-1.16	-11
Total Gross Profit	1.02	1.54	1.68	1.83	0.96
Total Revenue	4.12	5.94	5.14	5.43	4.73
Operating Revenue	4.12	5.94	5.14	5.43	4.73
Total Cost of Revenue	3.09	4.41	3.45	3.61	3.77
Operating Cost of Revenue	3.09	4.41	3.45	3.61	3.77
Total Operating Expenses	0.83	1.14	1.64	2.99	12
Selling, General & Admin Expense	0.80	1.10	1.62	2.78	10
Marketing Expense	0.02	0.04	0.02	0.21	1.19
Total Other Income / (Expense), net	-0.04	-0.05	0.07	0.20	20
Interest & Investment Income	-0.09	-0.08	-0.05	-0.77	-0.61
Other Income / (Expense), net	0.05	0.02	0.11	0.97	21
Income Tax Expense	0.29	0.21	0.00	-0.49	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.14	-0.32	-0.02	0.05	-0.15
Basic Earnings per Share	$0.00	$4.72	$13,019.30	($4,408.76)	$214.73
Weighted Average Basic Shares Outstanding	560K	28.80K	10.00	119.00	46.01K
Diluted Earnings per Share	-	$4.72	$13,019.30	($4,408.76)	$3.04
Weighted Average Diluted Shares Outstanding	-	28.80K	10.00	119.00	3.25M
Weighted Average Basic & Diluted Shares Outstanding	-	-	3.72M	113.85K	241.00K

No quarterly income statements for NewGenIvf Group are available.

This table details how cash moves in and out of NewGenIvf Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.13	-0.02	0.05	0.36	0.51
Net Cash From Operating Activities	1.43	1.71	-1.77	-8.26	-11
Net Cash From Continuing Operating Activities	1.43	1.71	-1.77	-8.26	-11
Net Income / (Loss) Continuing Operations	-0.14	0.14	0.11	-0.47	9.73
Consolidated Net Income / (Loss)	-0.14	0.14	0.11	-0.47	9.73
Depreciation Expense	0.17	0.10	0.03	0.02	0.19
Amortization Expense	0.18	0.20	0.20	0.19	0.31
Non-Cash Adjustments To Reconcile Net Income	0.21	0.57	-0.01	-0.24	-20
Changes in Operating Assets and Liabilities, net	1.02	0.70	-2.09	-7.76	-1.61
Net Cash From Investing Activities	-0.02	-0.09	-0.07	-0.05	-7.56
Net Cash From Continuing Investing Activities	-0.02	-0.09	-0.07	-0.05	-7.56
Purchase of Property, Plant & Equipment	-0.02	-0.09	-0.07	-0.05	-0.14
Acquisitions	-	-	0.00	0.00	-5.66
Other Investing Activities, net	-	-	0.00	0.00	-1.76
Net Cash From Financing Activities	-1.54	-1.63	1.88	8.68	19
Net Cash From Continuing Financing Activities	-1.54	-1.63	1.88	8.68	19
Repayment of Debt	-2.04	-1.74	1.86	0.51	-0.15
Issuance of Debt	0.51	0.13	0.00	8.58	6.84
Issuance of Common Equity	0.00	0.00	0.19	0.00	13
Other Financing Activities, net	-0.02	-0.02	-0.17	-0.42	-0.32
Cash Interest Paid	0.07	0.06	0.02	0.68	0.03
Cash Income Taxes Paid	0.00	0.01	0.00	0.00	0.00

No quarterly cash flow statements for NewGenIvf Group are available.

This table presents NewGenIvf Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2.90	4.49	3.58	33
Total Current Assets	2.40	2.46	3.17	7.38
Cash & Equivalents	0.03	0.05	0.46	0.76
Accounts Receivable	2.25	0.01	1.24	0.96
Inventories, net	0.05	0.27	0.08	0.34
Prepaid Expenses	0.07	1.77	0.39	0.50
Other Current Assets	-	0.35	1.00	4.83
Plant, Property, & Equipment, net	0.12	0.16	0.27	1.79
Total Noncurrent Assets	0.38	1.87	0.13	24
Noncurrent Note & Lease Receivables	-	-	0.03	0.00
Intangible Assets	-	-	0.00	21
Other Noncurrent Operating Assets	0.38	1.87	0.10	2.14
Total Liabilities & Shareholders' Equity	2.90	4.49	3.58	33
Total Liabilities	2.80	1.24	5.06	6.74
Total Current Liabilities	2.56	1.12	2.72	2.37
Short-Term Debt	-	0.00	0.58	0.26
Accounts Payable	0.39	0.41	1.80	1.49
Current Deferred & Payable Income Tax Liabilities	0.49	0.49	0.01	0.00
Other Current Liabilities	0.31	0.22	0.33	0.62
Total Noncurrent Liabilities	0.25	0.12	2.34	4.37
Long-Term Debt	-	0.00	2.33	4.10
Other Noncurrent Operating Liabilities	0.25	0.12	0.01	0.27
Total Equity & Noncontrolling Interests	0.10	3.25	-1.48	26
Total Preferred & Common Equity	0.56	3.74	-1.05	27
Total Common Equity	0.56	3.74	-1.05	27
Common Stock	1.46	4.33	0.12	18
Retained Earnings	-0.59	-0.46	-0.99	8.89
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.01	0.02	-0.14
Other Equity Adjustments	-0.32	-0.13	-0.20	0.00
Noncontrolling Interest	-0.46	-0.49	-0.43	-0.64

No quarterly balance sheets for NewGenIvf Group are available.

This table displays calculated financial ratios and metrics derived from NewGenIvf Group's official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	3,715,153.00	113,852.00	113,852.00
DEI Adjusted Shares Outstanding	0.00	0.00	62.00	2.00	2.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	2,099.89	-262,321.50	4,939,704.00
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	44.34%	-13.59%	5.79%	-13.01%
EBITDA Growth	0.00%	23.63%	-47.11%	-95.53%	63,084.11%
EBIT Growth	0.00%	72.55%	-63.46%	-222.73%	5,569.42%
NOPAT Growth	0.00%	189.31%	-73.17%	-2,023.08%	-1,220.43%
Net Income Growth	0.00%	527.51%	-59.86%	-518.57%	2,063.28%
EPS Growth	0.00%	0.00%	-59.86%	-518.57%	2,063.28%
Operating Cash Flow Growth	0.00%	19.39%	-203.23%	-367.92%	-32.21%
Free Cash Flow Firm Growth	0.00%	0.00%	-3,747.74%	145.75%	-2,895.26%
Invested Capital Growth	0.00%	0.00%	4,264.27%	-69.55%	2,943.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	24.88%	25.87%	32.74%	33.62%	20.22%
EBITDA Margin	14.25%	12.21%	7.47%	0.32%	229.40%
Operating Margin	4.83%	6.71%	0.82%	-21.36%	-226.95%
EBIT Margin	5.94%	7.09%	3.00%	-3.48%	218.83%
Profit (Net Income) Margin	-3.38%	10.00%	4.65%	-18.38%	414.86%
Tax Burden Percent	-89.04%	172.83%	220.08%	103.95%	201.55%
Interest Burden Percent	63.90%	81.57%	70.37%	508.08%	94.06%
Effective Tax Rate	188.70%	60.51%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	430.64%	2.59%	-39.02%	-70.21%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,741.51%	-478.36%	-54.56%	932.84%
Return on Net Nonoperating Assets (RNNOA)	0.00%	750.33%	11.67%	-74.22%	230.25%
Return on Equity (ROE)	0.00%	1,180.96%	14.26%	-113.25%	160.03%
Cash Return on Invested Capital (CROIC)	0.00%	230.64%	-188.45%	67.60%	-257.49%
Operating Return on Assets (OROA)	0.00%	14.52%	4.17%	-4.69%	56.98%
Return on Assets (ROA)	0.00%	20.47%	6.46%	-24.77%	108.03%
Return on Common Equity (ROCE)	0.00%	6,605.04%	18.32%	-172.52%	167.07%
Return on Equity Simple (ROE_SIMPLE)	0.00%	105.58%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.18	0.16	0.04	-0.81	-11
NOPAT Margin	-4.28%	2.65%	0.82%	-14.95%	-226.95%
Net Nonoperating Expense Percent (NNEP)	0.00%	3,172.15%	480.94%	15.54%	-1,003.06%
Return On Investment Capital (ROIC_SIMPLE)	-	156.39%	1.30%	-56.82%	-35.35%
Cost of Revenue to Revenue	75.12%	74.13%	67.26%	66.38%	79.78%
SG&A Expenses to Revenue	19.46%	18.55%	31.57%	51.19%	222.02%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.06%	19.16%	31.92%	54.98%	247.17%
Earnings before Interest and Taxes (EBIT)	0.24	0.42	0.15	-0.19	10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.59	0.73	0.38	0.02	11
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.28	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	314,399.01%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	3.63	0.10
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.65	0.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	205.43	0.27
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.29
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	2.51	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	-1.96	0.17
Long-Term Debt to Equity	0.00	0.00	0.00	-1.57	0.16
Financial Leverage	0.00	-0.27	-0.02	1.36	0.25
Leverage Ratio	0.00	28.85	2.21	4.57	1.48
Compound Leverage Factor	0.00	23.53	1.55	23.23	1.39
Debt to Total Capital	0.00%	0.00%	0.00%	203.65%	14.35%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	40.74%	0.84%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	162.91%	13.50%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-459.29%	-15.10%	-30.30%	-2.13%
Common Equity to Total Capital	0.00%	559.29%	115.10%	-73.35%	87.78%
Debt to EBITDA	0.00	0.00	0.00	169.66	0.40
Net Debt to EBITDA	0.00	0.00	0.00	142.99	0.33
Long-Term Debt to EBITDA	0.00	0.00	0.00	135.72	0.38
Debt to NOPAT	0.00	0.00	0.00	-3.58	-0.41
Net Debt to NOPAT	0.00	0.00	0.00	-3.02	-0.34
Long-Term Debt to NOPAT	0.00	0.00	0.00	-2.87	-0.38
Altman Z-Score	0.00	0.00	0.00	1.29	1.75
Noncontrolling Interest Sharing Ratio	0.00%	-459.29%	-28.46%	-52.34%	-4.40%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	0.94	2.19	1.17	3.12
Quick Ratio	0.00	0.89	0.06	0.62	0.73
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.08	-3.08	1.41	-39
Operating Cash Flow to CapEx	8,645.56%	1,811.40%	-2,528.54%	-15,579.36%	-8,091.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	2.05	1.39	1.35	0.26
Accounts Receivable Turnover	0.00	2.64	4.54	8.69	4.29
Inventory Turnover	0.00	93.93	22.06	20.78	18.12
Fixed Asset Turnover	0.00	48.46	36.06	24.97	4.58
Accounts Payable Turnover	0.00	11.17	8.54	3.26	2.29
Days Sales Outstanding (DSO)	0.00	138.40	80.42	42.00	85.01
Days Inventory Outstanding (DIO)	0.00	3.89	16.55	17.56	20.14
Days Payable Outstanding (DPO)	0.00	32.67	42.72	112.03	159.28
Cash Conversion Cycle (CCC)	0.00	109.61	54.24	-52.47	-54.12
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	0.07	3.19	0.97	30
Invested Capital Turnover	0.00	162.57	3.15	2.61	0.31
Increase / (Decrease) in Invested Capital	0.00	0.07	3.12	-2.22	29
Enterprise Value (EV)	0.00	0.00	0.00	3.53	2.95
Market Capitalization	0.00	0.00	0.00	1.50	0.00
Book Value per Share	$0.00	$19.55	$373,561.20	($0.28)	$233.91
Tangible Book Value per Share	$0.00	$19.55	$373,561.20	($0.28)	$45.82
Total Capital	0.00	0.10	3.25	1.43	30
Total Debt	0.00	0.00	0.00	2.91	4.35
Total Long-Term Debt	0.00	0.00	0.00	2.33	4.10
Net Debt	0.00	-0.03	-0.05	2.45	3.59
Capital Expenditures (CapEx)	0.02	0.09	0.07	0.05	0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-0.18	1.28	0.58	4.51
Debt-free Net Working Capital (DFNWC)	0.00	-0.16	1.34	1.03	5.27
Net Working Capital (NWC)	0.00	-0.16	1.34	0.45	5.02
Net Nonoperating Expense (NNE)	-0.04	-0.44	-0.20	0.19	-30
Net Nonoperating Obligations (NNO)	0.00	-0.03	-0.05	2.45	3.59
Total Depreciation and Amortization (D&A)	0.34	0.30	0.23	0.21	0.50
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-3.11%	24.97%	10.62%	95.52%
Debt-free Net Working Capital to Revenue	0.00%	-2.64%	26.02%	19.05%	111.57%
Net Working Capital to Revenue	0.00%	-2.64%	26.02%	8.33%	106.15%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$10,800.00	$0.00	$214.73
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	10.00	0.00	46.01K
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$3.04
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	62.00	0.00	3.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	62.00	0.00	241.00K
Normalized Net Operating Profit after Tax (NOPAT)	0.14	0.28	0.03	-0.81	-7.51
Normalized NOPAT Margin	3.38%	4.70%	0.58%	-14.95%	-158.86%
Pre Tax Income Margin	3.79%	5.79%	2.11%	-17.68%	205.84%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for NewGenIvf Group are available.

Financials Breakdown Chart

NewGenIvf Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NewGenIvf Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

NewGenIvf Group's net income appears to be on an upward trend, with a most recent value of $19.61 million in 2025, compared with -$139.07 thousand in 2021. The previous period was -$998.74 thousand in 2024. Check out NewGenIvf Group's forecast to explore projected trends and price targets.

NewGenIvf Group's total operating income in 2025 was -$10.73 million, based on the following breakdown:

Total Gross Profit: $955.85 thousand
Total Operating Expenses: $11.68 million

Over the last 4 years, NewGenIvf Group's total revenue changed from $4.12 million in 2021 to $4.73 million in 2025, a change of 14.8%.

NewGenIvf Group had total debt of $4.35 million at the end of 2025, a 49.5% increase from 2024, and none in 2021.

Over the last 4 years, NewGenIvf Group's book value per share changed from 0.00 in 2021 to 233.91 in 2025, a change of 23,391.4%.

Related Companies

Financial statements for NASDAQ:NIVF last updated on 10/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewGenIvf Group (NIVF) Financials

Financials Breakdown Chart

NewGenIvf Group Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewGenIvf Group (NIVF) Financials

Annual Income Statements for NewGenIvf Group

Quarterly Income Statements for NewGenIvf Group

Annual Cash Flow Statements for NewGenIvf Group

Quarterly Cash Flow Statements for NewGenIvf Group

Annual Balance Sheets for NewGenIvf Group

Quarterly Balance Sheets for NewGenIvf Group

Annual Metrics And Ratios for NewGenIvf Group

Quarterly Metrics And Ratios for NewGenIvf Group

Financials Breakdown Chart

NewGenIvf Group Financials - Frequently Asked Questions

When does NewGenIvf Group's financial year end?

How has NewGenIvf Group's net income changed over the last 4 years?

What is NewGenIvf Group's operating income?

How has NewGenIvf Group's revenue changed over the last 4 years?

How much debt does NewGenIvf Group have?

How has NewGenIvf Group's book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools